OSLO, Norway, June 14, 2019 /PRNewswire/ --
- Two posters to be presented at the 2019 annual congress of the European Hematology Association on 14th June
- Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy in elderly acute myeloid leukaemia (AML) patients unfit for intensive chemotherapy shows significant efficacy
- Preliminary responses reported in 6/14 (43%) patients, with CR/CRi in 4/14 (29%) patients; this is substantially higher than previously observed/historical benchmarks in single-agent cytarabine (low-dose chemotherapy)
- Median relapse-free survival 7.9 months in CR/CRi patients (data not mature)
- A second biomarker poster presented by Prof. Gjertsen, University Bergen, shows pharmacodynamic effects of bemcentinib on AML patients blast cell signal at just 4 hours post-dosing of bemcentinib
/PRNewswire/ -- BerGenBio ASA (OSE:BGBIO) today presents data showing significant efficacy in a Phase II clinical trial (BGBC003, NCT02488408) evaluating bemcentinib, a first-in-class selective oral AXL inhibitor, in combination with low-dose cytarabine (LDAC) as a potential new treatment regimen for AML patients unfit for intensive therapy. The data will be presented by Professor Bjørn Tore Gjertsen MD PhD, Haukeland University Hospital and University of Bergen, at the 2019 annual congress of the European Hematology Association (EHA24), in Amsterdam, The Netherlands, Friday, June 14, 2019.
In total, 16 patients were enrolled into the trial. Among the 14 patients evaluable for efficacy, 6 responses have been reported; 4 patients achieved complete remission / complete remission with incomplete hematologic recovery (CR/CRi) and 2 patients achieved partial remission (PR). Five of the six responses occurred among elderly AML patients (>75 years). Furthermore, two patients achieved durable stable disease for more than 3 months. The relapse-free survival rate for patients with CR/CRi is 7.9 months (range: 0.7 to 9.6 months) and continues to mature. The combination treatment of bemcentinib and LDAC was overall well-tolerated; the most common adverse events (>15% of patients) included anaemia, neutropenia and diarrhoea. Soluble protein (e.g. sAXL) and gene expression biomarker data is still maturing and will be reported in due course. A second biomarker poster from Prof. Gjertsen's group, to be presented on June 15th, examined the effect of bemcentinib monotherapy from a phase 1b/2 clinical trial on patient AML cell signal transduction using mass cytometry. The high-dimensional single cell-level signalling analysis of AML blasts from 6 evaluable patients revealed significant effects already at 4 hours post-dosing of bemcentinib.
Professor Bjørn Tore Gjertsen commented: "These early results are encouraging, especially among less fit AML patients with comparatively poor prognosis. Bemcentinib in combination with LDAC resulted in a substantially higher ORR than expected for single-agent cytarabine and clearly warrant further investigation of bemcentinib in an expansion cohort of AML patients unfit for intensive chemotherapy. Our signal cell-level biomarker analysis of AML blasts from patients indicates a substantial effect on cell signalling and represents a potential new biomarker strategy."
Richard Godfrey, Chief Executive Officer of BerGenBio, commented: "There are currently limited treatment options for AML patients unable to tolerate intensive chemotherapy, particularly those with relapsed and refractory disease. These promising preliminary data with bemcentinib in combination with low-dose cytarabine, reinforce data we recently at presented at ASCO, and suggests that the addition of our selective AXL inhibitor can substantially improve AML patient outcomes. I am particularly encouraged by the high response rate observed in all patient groups studied, the extended duration of responses seen, which is still maturing, and how well the combination therapy was tolerated. We are still waiting on much of our biomarker data before we can report that and are very excited by cell signalling data presented by our collaborators at the University of Bergen. We will expand this study to include more patients and report more complete data in the coming months.
The posters presented at EHA will be made available at www.bergenbio.com in the Investors / Presentations section to coincide with the following conference sessions:
Friday 14 June, 17:30 - 19:00 Central European Time
The Combination of bemcentinib, a novel, oral, selective AXL-Inhibitor and Low-Dose Cytarabine yields Durable Responses in AML patients Unfit for Intensive Chemotherapy
- Author: Sonja Loges et al.
- Abstract: PF259
- Location: Poster area
Saturday 15 June, 17:30 - 19:00 Central European Time
Single Cell Signaling Pharmacodynamics in a Phase 1b Clinical Trial of the AXL inhibitor bemcentinib in Acute Myeloid Leukemia and Myelodysplastic Syndrome
- Author: Monica Hellesøy et al.
- Abstract: PS999
- Location: Poster area
About AML and the BGBC003 Trial
Acute myeloid leukaemia (AML) is a rapidly progressing blood cancer. AML is the most common form of acute leukaemia in adults, where malignant AML blasts interfere with the normal functioning of the bone marrow leading to a multitude of complications like anaemia, infections and bleeding. AML is diagnosed in over 20,000 patients in the US annually and is rapidly lethal if left untreated. Successful treatment typically requires intensive therapy or bone marrow transplantation, and relapse and resistance are common. Consequently, there is an urgent need for effective novel therapies in relapsed/refractory patients, particularly those that are ineligible for intensive therapy or bone marrow transplant.
The BGBC003 trial is a phase Ib/II multi-centre open label study of bemcentinib in combination with cytarabine (part B2) and decitabine (part B3) in patients with AML who are unsuitable for intensive chemotherapy as a result of advanced age or existing-co-morbidities. Up to 28 patients will be enrolled at centres in the US, Norway, Germany and Italy.
For more information please access trial NCT02488408 at www.clinicaltrials.gov.
AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying life-threatening diseases. In cancer, AXL suppresses the body's immune response to tumours and drives cancer treatment failure across many indications. AXL inhibitors, therefore, have potential high value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities. Research has also shown that AXL mediates other aggressive diseases.
Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme. Ongoing clinical trials are investigating bemcentinib in multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as a single agent. Bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL receptor tyrosine kinase and inhibits its activity. Increase in AXL function has been linked to key mechanisms of drug resistance and immune escape by tumour cells, leading to aggressive metastatic cancers.
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer and leukaemia. A first-in-class functional blocking AXL antibody (BGB149) and an AXL-ADC (ADCT-601) are undergoing phase I clinical testing. In parallel, BerGenBio is developing a companion diagnostic test to identify those patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). www.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
Richard Godfrey CEO, BerGenBio ASA
Rune Skeie, CFO, BerGenBio ASA
International Media Relations:
Mary-Jane Elliott, Chris Welsh, Jessica Hodgson, Nicholas Brown, Carina Jurs
Consilium Strategic Communications
Media Relations in Norway:
Jan Petter Stiff, Crux Advisers
This information was brought to you by Cision http://news.cision.com